Tonix Pharma Shares FDA Response For COVID-19 Vaccine Candidate Human Study

by Vandana Singh, Benzinga Editor

September 13, 2021 9:44 AM | 1 min read | Make a Comment

Tonix Pharmaceuticals Holding Corp TNXP announced that it received the official written response from a Type B pre-Investigational New Drug (IND) meeting with the FDA for its COVID-19 vaccine candidate.
Based on the response, the Company expects to begin a Phase 1 study in 1H of 2022.
TNX-1800 is a live modified horsepox virus vaccine designed to express the Spike protein of the SARS-CoV-2 virus and elicit a predominant T cell response.
Related Content: Tonix Pharma To Start Mid-Stage Long COVID Trial In Q4.
Price Action: TNXP shares are up 0.02% at $0.66 during the market session on the last check Monday.

Posted In: Biotech News Penny Stocks Health Care General Briefs COVID-19 Coronavirus COVID-19 Vaccine Preclinical Phase

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.